tbuckley/cabot-search huggingface dataset:
Abstract #3119: Transcriptional profiling identifies the signaling axes of the insulin-like growth factor and the transforming growth factor-\#946; in the pathogenesis of osteosarcoma
Authors: Rui Yang, Sajida Piperdi, Yue Zhang, Neophytou Neophytos, Wei Zhu, Bang Hoang, Gary Mason, David Geller, Howard Dorfman, John Healey, Donald Phinney, Richard Gorlick
Journal: Cancer Research (2009)

Osteosarcoma is the most common primary bone tumor in adolescents associated with skeletal development. The molecular pathogenesis of osteosarcoma is unknown. The whole-genome transcriptional profiles of osteosarcomas, including two primary biopsy specimens, two cell lines, two patient specimen-derived xenografts, and normal osteoblasts and mesenchymal stem cells (MSC) were quantitatively measured using serial analysis of gene expression (SAGE). A two-step statistical enrichment was performed, which selects those common genes altered in each of the osteosarcomas as compared with each of the normal counterparts independently. Sixty (92%) of 65 total genes that were down-regulated in osteosarcoma could be classified into four categories: 1) seven genes in the insulin-like growth factor (IGF) signaling axis, including three of the IGF binding proteins (IGFBP) and three of the IGFBP related proteins (IGFBPrP); 2) eight genes in the transforming growth factor-beta (TGF-\#946;)/bone morphogenetic proteins (BMP) signaling cascade; 3) thirty-nine genes encoding cytoskeleton and extracellular matrix proteins that are regulated by TGF-\#946;/BMPs; and 4) six genes involved in cell cycle regulation, including tumor suppressors TP63 and p21. Based on these transcriptional profiles, a coordinated theme of clustered gene deregulation in osteosarcoma has emerged. Cell proliferation driven by the IGF axes during bone growth is unrestrained due to down-regulation of IGFBPs and cell cycle regulators. Tumor cells may be maintained in an undifferentiated state secondary to impaired TGF-\#946;/>/BMP signaling. This well-preserved pattern suggests that the alterations in the signaling axes of IGF-1 and TGF-\#946;, in concert with cell cycle regulators, may be the pathogenic basis of osteosarcoma.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3119.
Comparison of Seven Generic Enoxaparins with Lovenox® on In Vitro Cross-Reactivity with Antibodies From Heparin Induced Thrombocytopenia.
Authors: Vassiliki Galea, Grigoris T Gerotziafas, Mouna Sassi, Jawed Fareed, Jeanine M. Walenga, Ismail Elalamy
Journal: Blood (2010)
OPTIMIZATION of the Cultivation of Mesenchymal STEM CELLS for CLINICAL USE
Authors: Vanessa de Souza Valim, Fernanda Oliveira, Maria Aparecida Lima da Silva, Bruna Amorin, Lauro Moraes, Annelize Pezzi, Alice Dahmer, Regina Carvalho, Natália Lemos, Letícia Baggio, Nathália Kersting, Filipi Sehn, Gabriela Melchiades, Liane Daudt, Lucia Silla
Journal: Blood (2011)
Rare Cancer Center - All Activities for Rare Cancer Patients! -
Authors: Yoko Katoh, Akira Kawai, Taro Shibata, Yasushi Goto, Tatsuya Suzuki, Shintaro Iwata, Kan Yonemori, Wataru Munakata, Eriko Satomi, Akihiko Yoshida, Takuro Sakurai, Tomoko Takayama, Takahiro Higashi, Tosirou Nishida
Journal: Annals of Oncology (2019)
“Non-Hodgkin's Lymphomas and Diabetes of Type 2 in Elderly Patients: Impact On Management in the Real Life”.
Authors: Stephane Moreau, Liliane Remenieras, Mohamed Touati, Marie Jose RAPP, Marie-Pierre Gourin, Frederica Bompart, Nicolas Weinbreck, Sophie Lefort, Dominique Devesa-Mansour, Jean Feuillard, Arnaud Jaccard, Dominique Bordessoule
Journal: Blood (2009)
Inferior Progression-Free Survival after Autotransplant for Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma in Patients &gt; 60 Versus ≤ 60 Years of Age.
Authors: John Kuruvilla, Vikas Gupta, Yael Zaretsky, Sahar Zadeh, Tracy Nagy, Armand Keating, Michael Crump
Journal: Blood (2006)
2nd line bevacizumab(BEV) continuation chemotherapy(Cx) beyond early progression for metastatic colorectal cancer(mCRC)
Authors: Masato Komoda, Shun Yamamoto, Takeshi Kawakami, Seiichiro Mitani, Yasushi Tsuji, Naoki Izawa, Kentaro Kawakami, Yoshiyuki Yamamoto, Akitaka Makiyama, Kentaro Yamazaki, Toshiki Masuishi, Taito Esaki, Takashi Tsuda, Hiroyuki Okuda, Toshikazu Moriwaki, Narikazu Boku
Journal: Annals of Oncology (2019)
Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia.
Authors: Miki Takeuchi, Junya Kuroda, Shinya Kimura, Eishi Ashihara, Kazuo Umezawa, Eiko Yasui, Makoto Kawatani, Hiroyuki Osada, Keiko Hodohara, Yoshihide Fujiyama, Taira Maekawa
Journal: Blood (2007)
Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL
Authors: Denis-Claude Roy, Silvy Lachance, Jean Roy, Irwin Walker, Johan Maertens, Jean-Sebastien Delisle, Stephen Ronan Foley, Philippe Lewalle, Eduardo Olavarria, Dominik Selleslag, Manfred Rüdiger, Jurjen Velthuis, Lisya Gerez, Jeroen Rovers, Halvard Bonig, Stephan Mielke
Journal: Blood (2016)
3-Hydroxyanthralinic acid metabolism controls the hepatic SREBP/lipoprotein axis, inhibits inflammasome activation in macrophages, and decreases atherosclerosis in Ldlr−/− mice
Authors: Martin Berg, Konstantinos A Polyzos, Hanna Agardh, Roland Baumgartner, Maria J Forteza, Ilona Kareinen, Anton Gisterå, Gerhard Bottcher, Eva Hurt-Camejo, Göran K Hansson, Daniel F J Ketelhuth
Journal: Cardiovascular Research (2019)

Atherosclerosis is a chronic inflammatory disease involving immunological and metabolic processes. Metabolism of tryptophan (Trp) via the kynurenine pathway has shown immunomodulatory properties and the ability to modulate atherosclerosis. We identified 3-hydroxyanthranilic acid (3-HAA) as a key metabolite of Trp modulating vascular inflammation and lipid metabolism. The molecular mechanisms driven by 3-HAA in atherosclerosis have not been completely elucidated. In this study, we investigated whether two major signalling pathways, activation of SREBPs and inflammasome, are associated with the 3-HAA-dependent regulation of lipoprotein synthesis and inflammation in the atherogenesis process. Moreover, we examined whether inhibition of endogenous 3-HAA degradation affects hyperlipidaemia and plaque formation.In vitro, we showed that 3-HAA reduces SREBP-2 expression and nuclear translocation and apolipoprotein B secretion in HepG2 cell cultures, and inhibits inflammasome activation and IL-1β production by macrophages. Using Ldlr-/- mice, we showed that inhibition of 3-HAA 3,4-dioxygenase (HAAO), which increases the endogenous levels of 3-HAA, decreases plasma lipids and atherosclerosis. Notably, HAAO inhibition led to decreased hepatic SREBP-2 mRNA levels and lipid accumulation, and improved liver pathology scores.We show that the activity of SREBP-2 and the inflammasome can be regulated by 3-HAA metabolism. Moreover, our study highlights that targeting HAAO is a promising strategy to prevent and treat hypercholesterolaemia and atherosclerosis.
Association between QoL and Gastrointestinal Chemotherapy Toxicity in Breast Cancer Patient: A Preliminary study
Authors: Felix Wijovi, Fernando Dharmaraja, Helenia Putri, Wilson M. Raffaello, Julang Fahman, Olivia J.D.A. Saroso, Devina A. Halim, Angeline Tancherla, Friecelie Natalie, Andree Kurniawan
Journal: Annals of Oncology (2019)
The Point-of-Care INR Test for Vitamin K Antagonist Monitoring
Authors: Irsk Anderson, Geoffrey D. Wool, William Madden
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A pharmacokinetics study of edoxaban in NSCLC patients harboring an EGFR mutation combined with venous thromboembolism
Authors: Takamasa Hotta, Yukari Tsubata, Nobuhisa Ishikawa, Akari Tanino, Misato Kobayashi, Jun Sugisaka, Atsushi Nakamura, Takae Okuno, Junro Umemoto, Mika Nakao, Megumi Hamaguchi, Shunichi Hamaguchi, Masahumi Hongo, Nobuhiro Nishimura, Masahiro Yamasaki, Kazunori Fujitaka, Tetsuya Kubota, Takeshi Isobe
Journal: Annals of Oncology (2019)
Understanding United States (US) Treatment Practices for the Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: A US Subgroup Analysis of the WORLD CML Registry.
Authors: Robert Hermann, Carole B. Miller, Rosalind Catchatorian, David S. Snyder, Solveig G. Ericson, Oleg Zernovak, Matthews A Juma, Jorge E. Cortes
Journal: Blood (2012)
Modulation of Activin Signaling by RAP-011 (ActRIIA-IgG1) Improve Anemia, Increases Hemoglobin Levels and Corrects Ineffective Erythropoiesis in β-Thalassemia
Authors: Michael Dussiot, Thiago Maciel, Aurelie Fricot, Joel Veiga, Etienne Paubelle, Emmanuel Payen, Yves Beuzard, Jean-Antoine Ribeil, Jean-Benoît Arlet, Genevieve Courtois, Tom O Daniel, Rajesh Chopra, Victoria Sung, Olivier Hermine, Ivan Cruz Moura
Journal: Blood (2012)
Germline Mutations in CBL Cause a Predisposition to Juvenile Myelomonocytic Leukemia.
Authors: Charlotte M Niemeyer, Michelle Kang, Ingrid Furlan, Danielle Shin, Debbie S Sakai, Andrea Heinzmann, Sophie Archambeault, Jerry Z. Finklestein, Parinda Mehta, Michael H Albert, Gabriele Kropshofer, Selim Corbacioglu, Peter J. Lang, Miriam Erlacher, Jan Stary, Marry M. van den Heuvel, Henrik Hasle, Franco Locatelli, Kevin Shannon, Benjamin S. Braun, Christian Flotho, Mignon L. Loh
Journal: Blood (2009)
Leveraging Increased Nucleoside Kinase Activity to Selectively Deplete Mitochondrial DNA (mtDNA), Impair Oxidative Phosphorylation, and Target AML Cells
Authors: Sanduni U. Liyanage, Rose Hurren, Veronique Voisin, Wang Xiaoming, Gaëlle Bridon, Changjiang Xu, Neil MacLean, Thirushi Siriwardena, Aisha Shamas-Din, Shrivani Sriskanthadevan, Mark D. Minden, Gary D Bader, Rebecca Laposa, Aaron D. Schimmer
Journal: Blood (2016)
Result of FDG PET-CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: An Analysis From the PRIMA Study
Authors: Judith Trotman, Marion Fournier, Thierry Lamy, Jane A Estell, Anne Sonet, Andrea Janikova, Herve Tilly, Didier Decaudin, Jean Gabarre, John F Seymour, Etienne Garin, Cecily Forsyth, Michael Fulham, Thierry Vander Borght, Ofer Shpilberg, Gilles Salles
Journal: Blood (2010)
Bioluminescence in Vivo Imaging Improves the Model of Individual Patients' AML Cells Growing in Mice for Sensitive and Reliable Preclinical Treatment Trials on Various Genetic Subgroups
Authors: Irmela Jeremias, Binje Vick, Maya Rothenberg, Nadine Sandhöfer, Michela Carlet, Christina Krupka, Andreas Trumpp, Selim Corbacioglu, Martin Ebinger, Maya Caroline Andre, Wolfgang Hiddemann, Stephanie Schneider, Marion Subklewe, Klaus H Metzeler, Karsten Spiekermann
Journal: Blood (2014)
Von Willebrand factor delays liver repair after acetaminophen-induced acute liver injury in mice
Authors: Dafna Groeneveld, Holly Cline-Fedewa, Kevin S. Baker, Kurt J. Williams, Robert A. Roth, Karen Mittermeier, Ton Lisman, Joseph S. Palumbo, James P. Luyendyk
Journal: Journal of Hepatology (2019)
A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
Authors: Michelle A. Fanale, Luis E. Fayad, Barbara Pro, Felipe Samaniego, Gracy Zachariah, Cesar A. Nunez, Yuan Ji, Anas Younes
Journal: Blood (2008)
Impact of Allogeneic Transplantation From Matched Related and Unrelated Donors on Clinical Outcome In Younger Adult AML Patients with FLT3 Internal Tandem Duplications
Authors: Sabine Kayser, Konstanze Döhner, Jürgen Krauter, Jochen Casper, Heinz A. Horst, Gerhard Held, Sibylla Wilhelm, Guido Kobbe, Michael Lübbert, Helmut R. Salih, Katharina Götze, Mathias J. Rummel, Walter Fiedler, Marie von Lilienfeld-Toal, David Nachbaur, Mohammed Wattad, Daniela Späth, Patricia Erdmann, Arnold Ganser, Hartmut Döhner, Richard F. Schlenk
Journal: Blood (2010)
Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Authors: Michelle B. Riba, Kristine A. Donovan, Barbara Andersen, IIana Braun, William S. Breitbart, Benjamin W. Brewer, Luke O. Buchmann, Matthew M. Clark, Molly Collins, Cheyenne Corbett, Stewart Fleishman, Sofia Garcia, Donna B. Greenberg, Rev. George F. Handzo, Laura Hoofring, Chao-Hui Huang, Robin Lally, Sara Martin, Lisa McGuffey, William Mitchell, Laura J. Morrison, Megan Pailler, Oxana Palesh, Francine Parnes, Janice P. Pazar, Laurel Ralston, Jaroslava Salman, Moreen M. Shannon-Dudley, Alan D. Valentine, Nicole R. McMillian, Susan D. Darlow
Journal: Journal of the National Comprehensive Cancer Network (2019)

Distress is defined in the NCCN Guidelines for Distress Management as a multifactorial, unpleasant experience of a psychologic (ie, cognitive, behavioral, emotional), social, spiritual, and/or physical nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment. Early evaluation and screening for distress leads to early and timely management of psychologic distress, which in turn improves medical management. The panel for the Distress Management Guidelines recently added a new principles section including guidance on implementation of standards of psychosocial care for patients with cancer.
Unraveling the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms through Whole Exome Sequencing
Authors: Benjamin Durham, Jing Ma, Eunhee Kim, John K. Choi, Patrick Campbell, Juvianee Estrada-Veras, Michael P Walsh, Mario E Lacouture, Young Rock Chung, Joy Nakitandwe, Eli Diamond, David M. Hyman, Raajit K. Rampal, Minal Patel, Christopher Y. Park, Tanja A. Gruber, Omar Abdel-Wahab
Journal: Blood (2014)
Combination Targeted Therapy to Impair Self-Renewal Capacity of Human Blast Crisis Leukemia Stem Cells
Authors: Angela C Court Recart, Anil Sadarangani, Daniel Goff, Alice Y Shih, Russell Wall, Heather Leu, Wenxue Ma, Christian L Barrett, Kelly A Frazer, Elizabeth Chun, Marco A. Marra, Catriona Jamieson
Journal: Blood (2011)
NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance
Authors: Ansu Abu Alex, Hamenth Kumar P, Saravanan Ganesan, Nithya Balasundaram, Kavitha M Lakshmi, Biju George, Aby Abraham, Auro Viswabandya, Alok Srivastava, Rose Ann Padua, Christine Chomienne, Poonkuzhali Balasubramanian, Vikram Mathews
Journal: Blood (2013)
Severe Depression Following Recovery From Thrombotic Thrombocytopenic Purpura (TTP)
Authors: Cassandra C. Deford, Lauren H. Schwartz, Jedidiah J. Perdue, Jessica A. Reese, Johanna A. Kremer Hovinga, Bernhard Lämmle, Lauren M. Stewart, Zayd L. Al-Nouri, Deirdra R. Terrell, James N. George, Sara K. Vesely
Journal: Blood (2012)
CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia
Authors: Swagata Goswami, Rajeswaran Mani, Chi-Ling Chiang, Frank W Frissora, Xiaokui Mo, Zhiliang Xie, Donna Bucci, Amber Gordon, David M. Lucas, William Blum, Alison R. Walker, Alice S. Mims, Rebecca B Klisovic, Ching-Shih Chen, Robert J Lee, John C. Byrd, Mitch A. Phelps, Sumithira Vasu, Natarajan Muthusamy
Journal: Blood (2016)
Activation of Acute Lymphocytic Leukemia Blasts with CpG ODN, IL-4 and CD40 Ligand Facilitates Enhanced Anti-Leukemic CTL Responses
Authors: Dorit Fabricius, Lucia Breckerbohm, Manon Queudeville, Angelika Vollmer, Sarah M. Eckhoff, Johanna Pfeil, Gudrun Strauss, Simone Fulda, Bernd Jahrsdoerfer, Lueder H Meyer, Klaus-Michael Debatin
Journal: Blood (2010)
The Basic Helix-Loop-Helix TAL1/SCL and Its Partners E47 and LMO2 Act Upstream of the VE-Cadherin Gene in Endothelial Cells.
Authors: Virginie Deleuze, Elias Chalhoub, Rawan El-Hajj, Christiane Dohet, Mikael Le Clech, Philippe Huber, Daniele Mathieu
Journal: Blood (2006)
LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma
Authors: Yan Xu, Yuan Li, Jiankang Jin, Guangchun Han, Chengcao Sun, Melissa Pool Pizzi, Longfei Huo, Ailing Scott, Ying Wang, Lang Ma, Jeffrey H. Lee, Manoop S. Bhutani, Brian Weston, Christopher Vellano, Liuqing Yang, Chunru Lin, Youngsoo Kim, A. Robert MacLeod, Linghua Wang, Zhenning Wang, Shumei Song, Jaffer A. Ajani
Journal: Molecular Cancer (2019)

Abstract Background PVT1 has emerged as an oncogene in many tumor types. However, its role in Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC) is unknown. The aim of this study was to assess the role of PVT1 in BE/EAC progression and uncover its therapeutic value against EAC. Methods PVT1 expression was assessed by qPCR in normal, BE, and EAC tissues and statistical analysis was performed to determine the association of PVT1 expression and EAC (stage, metastases, and survival). PVT1 antisense oligonucleotides (ASOs) were tested for their antitumor activity in vitro and in vivo. Results PVT1 expression was up-regulated in EACs compared with paired BEs, and normal esophageal tissues. High expression of PVT1 was associated with poor differentiation, lymph node metastases, and shorter survival. Effective knockdown of PVT1 in EAC cells using PVT1 ASOs resulted in decreased cell proliferation, invasion, colony formation, tumor sphere formation, and reduced proportion of ALDH1A1 + cells. Mechanistically, we discovered mutual regulation of PVT1 and YAP1 in EAC cells. Inhibition of PVT1 by PVT1 ASOs suppressed YAP1 expression through increased phosphor-LATS1and phosphor-YAP1 while knockout of YAP1 in EAC cells significantly suppressed PVT1 levels indicating a positive regulation of PVT1 by YAP1. Most importantly, we found that targeting both PVT1 and YAP1 using their specific ASOs led to better antitumor activity in vitro and in vivo. Conclusions Our results provide strong evidence that PVT1 confers an aggressive phenotype to EAC and is a poor prognosticator. Combined targeting of PVT1 and YAP1 provided the highest therapeutic index and represents a novel therapeutic strategy.
Treatment with Intravenous Immunoglobulin Does Not Prevent Chronic Immune Thrombocytopenia in Children: Results of a Randomized Controlled Trial
Authors: Katja M.J. Heitink-Polle, Cuno S.P.M. Uiterwaal, Leendert Porcelijn, Rienk Y.J. Tamminga, Frans J Smiers, Nicole L. van Woerden, Judith Wesseling, Annemieke G. Laarhoven, Masja de Haas, Marrie C.A. Bruin
Journal: Blood (2016)
Dietary ω-3 Fatty Acid Supplementation As a Potential New Therapy for Vasculopathy in Sickle Cell Disease: Proof of Concept in a Transgenic Mouse Model
Authors: Brian T Kalish, Alessandro Matte, Immacolata Andolfo, Achille Iolascon, Olga Weinberg, Angela Siciliano, Enrica Federti, Mark Puder, Carlo Brugnara, Lucia De Franceschi
Journal: Blood (2014)
Haptoglobin Therapy Prevents Kidney Injury in Stored Blood Resuscitation of Murine Hemorrhagic Shock
Authors: Jan A. Graw, Ivy A. Rosales, Yumin Liu, Venkata S. Sabbisetti, Frank E. Riley, Osher Rechester, Kenneth D. Bloch, H. Shaw Warren, Joseph V. Bonventre, Warren M. Zapol
Journal: Blood (2014)
Mumps in Migrant Detention Centers
Authors: Bridget Kuehn
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Successful Autologous Peripheral Blood Stem Cell Transplantation In Severe Refractory Dermatomyositis
Authors: Francesca Saltarelli, Raffaele D’Amelio, Raffaele Porrini, Giovanni Antonini, Antonella Ferrari, Esmeralda Conte, Francesca Milanetti, Bruno Laganà, Giusy Antolino, Enrico Montefusco
Journal: Blood (2011)
Impact of Individual Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia
Authors: Max J. Gordon, Michael C Churnetski, Hamood Alqahtani, Xavier Issac Rivera, Adam Kittai, Nur Bruss, Sheila Hoff, Michael Y. Choi, Jonathon B. Cohen, Daniel Persky, Byung Park, Alexey V Danilov
Journal: Blood (2018)
Neural EGFL like 1 as a potential pro-chondrogenic, anti-inflammatory dual-functional disease-modifying osteoarthritis drug
Authors: Chenshuang Li, Zhong Zheng, Pin Ha, Wenlu Jiang, Emily A. Berthiaume, Seungjun Lee, Zane Mills, Hsinchuan Pan, Eric C. Chen, Jie Jiang, Cymbeline T. Culiat, Xinli Zhang, Kang Ting, Chia Soo
Journal: Biomaterials (2019)
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL): The Clinical Implications of Earlier Diagnosis and Longer Follow-Up.
Authors: Clive S. Zent, Susan L. Slager, Wei Ding, Karin F. Giordano, Susan M. Schwager, James D. Hoyer, Timothy G. Call, Tait D. Shanafelt, Neil E. Kay
Journal: Blood (2006)
Matched HLA Haplotype Contributes to Reduce Sever Acute GVHD with Conserving GVL Effect in HLA-Mismatched Cord Blood Transplantation,
Authors: Satoshi Takahashi, Jun Ooi, Seiko Kato, Toshiro Kawakita, Arinobu Tojo, Yasuhiro Ebihara, Shinji Mochizuki, Shohei Yamamoto, Kohichiro Tsuji, Takuhiro Yamaguchi, Satoko Morishima, Yasuo Morishima, Shigetaka Asano
Journal: Blood (2011)
Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations
Authors: Daniela Barraco, Sonia Cerquozzi, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Journal: Blood (2016)
Elevated Levels of Cytokines and Chemokines in Patients with Antiphospholipid (aPL) Antibodies.
Authors: Silvia S Pierangeli, Laura Aline Martinez-Martinez, Renan Aguilar-Valenzuela, Gerald Mc Gwin, Ellis Doan, Elizabeth Papalardo, Jo Ann Vega, Emilio B. Gonzalez, Vijaya Murthy, Alan SEif, Doruk Erkan
Journal: Blood (2009)
Analysis of Stem Cell Populations Circulating in Peripheral Blood in Preterm Infants: Circulating Endothelial Progenitior Cells and Plasma VEGF and HGF Level as a Novel Prognostic Factors for Development of Retinopathy of Prematurity.
Authors: Anna Machalinska, Monika Modrzejewska, Maciej Kotowski, Magdalena Kucia, Milosz Kawa, Magdalena Baskiewicz-Masiuk, Jacek Rudnicki, Boguslaw Machaliñski
Journal: Blood (2009)